Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma
European Journal of Cancer2010Vol. 46(15), pp. 2753–2762
Citations Over TimeTop 15% of 2010 papers
Franck Bonnetain, Laëtitia Dahan, E. Maillard, Marc Ychou, Emmanuel Mitry, Pascal Hammel, Jean-Louis Legoux, Philippe Rougier, Laurent Bedenne, Jean‐François Seitz
Related Papers
- → A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer(2013)35 cited
- Comparison of Gemcitabine monotherapy with Gemcitabine and Cisplatin combination in metastatic pancreatic cancer: a retrospective analysis.(2018)
- → EFFORTS TO IMPROVE THE ANTI-TUMOR EFFECT OF GEMCITABINE IN HUMAN PANCREATIC CANCER(2008)
- → A Comparison of Gemcitabine in Two Doses for Stage III or IV Non-small Cell Lung Cancer: a Multi-Institutional Phase II Study(2007)
- Gemcitabine alone versus gemcitabine plus carboplatin in treatment of elderly patients with advanced non-small cell lung cancer(2011)